p53-R280S mutation confers lenvatinib resistance in hepatocellular carcinoma via Bcl-2-mediated anti-apoptotic signaling
RNA sequencing of lenvatinib-resistant HCC cell lines revealed p53 dysregulation, and sanger sequencing identified the p53 R280S missense mutation, which was shown to enhance lenvatinib resistance in vitro and in vivo.